IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 3839 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded289    
    Comments [Add]    
    Cited by others 4    

Recommend this journal


Year : 2020  |  Volume : 52  |  Issue : 1  |  Page : 10-15

A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression

Department of Psychiatry, MM Institute of Medical Sciences and Research, Ambala, Haryana, India

Correspondence Address:
Dr. Shazia Anjum
H. No. 152 (Inside Sirhindi Gate), Sangrur, Malerkotla - 148 023, Punjab
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijp.IJP_618_18

Rights and Permissions

BACKGROUND: Depressive disorders are considered to be one of the leading causes of morbidity and mortality accounting for 4.3% of total disability-adjusted life years. Selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors have greater efficacy and lesser side effects; at the same time, these drugs cause sexual dysfunction and weight gain. Vilazodone was supposed to have better efficacy and less sexual dysfunction and weight gain. AIM OF THE STUDY: The aim is to compare efficacy (in terms of Hamilton Depression Rating Scale [HDRS]), sexual dysfunction (in terms of Arizona Sexual Experience Scale [ASEX]), and weight gain caused due to vilazodone and sertraline. MATERIALS AND METHODS: This is a randomized controlled study; 60 patients diagnosed with depressive episode were divided into two groups of 30 each; using block randomization technique, one group was prescribed vilazodone and another sertraline. The groups were compared on the basis of efficacy, weight gain, and sexual dysfunction using HDRS and ASEX at baseline, 4-week, and 12-week intervals. Statistical analysis was done by applying Chi-square test, Fisher's exact test, t- test, and repeated measures ANOVA using Wilks' lambda test. RESULTS: On comparing both vilazodone and sertraline, it was observed that both molecules have equal efficacy in terms of HDRS, but vilazodone does not cause weight gain and sexual dysfunction in terms of ASEX, and these findings are statistically very highly significant. CONCLUSIONS: Our study shows that vilazodone has similar efficacy but can be a better antidepressant due to lesser weight gain and sexual dysfunction compared to sertraline.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow